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interruption strategy did not increase the costs related to adverse
events or consultations.
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OBJECTIVES: To analyze the cost-minimization of Daptomycin
in comparison to Vancomycin and Linezolid for patients with
Methicillin Resistant Staphylococcus Aureus (MRSA) skin and
soft tissues infections in Brazilian private payer perspective.
METHODS: The alternatives were indirectly compared due to
the absence of Head to Head studies. Resource consumption for
MRSA treatment were collected from previous publication and
divided into two categories: hospital care (including diagnostic
tests) and pharmaceuticals. Total treatment cost was investigated
for a base case where patients were treated in the best proﬁle
for each medicine effectiveness based on values extracted from
randomized open or blind studies [Daptomycin: Length of stay
(LOS) = 4 days with intravenous drug. Vancomycin: LOS = 7
days with intravenous drug. Linezolid: LOS = 4 days with intra-
venous drug and 11 days with oral drug]. The costs data regard-
ing medicines were collected from companies price list or price
submission process and utilization costs from literature. Results
were converted in US Dollars (R$ 1.7/USD 1.00). A one-way
sensitivity analysis was performed. RESULTS: For base case the
total treatment was US$1,646.89 for Daptomycin, US$1,843.84
for Vancomycin and US$3,290.46 for Linezolid. Pharmaceutical
inpatient cost was US$129.93 higher for Daptomycin in com-
parison with Linezolid and US$868,31 higher when compared
with generic-vancomycin; however this cost was offset by shorter
LOS. Despite the unitary prices of the Vancomycin and Linezolid
are lower than the price of Daptomycin, the total treatment costs
with Linezolid and generic-vancomycin is higher than with Dap-
tomycin. The sensitivity analysis on costs variables in an interval
of +/-20%, was robust with the base case. CONCLUSIONS: The
Daptomycin is a cost-saving alternative for MRSA skin and soft
tissues infections compared to generic-vancomycin and linezolid
in the perspective of Brazilian private payer.
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OBJECTIVES: Irrational antibiotic usage is still common in
Turkey and antibiotics are still the most commonly used drug in
Turkey. Our aim in this study was to evaluate the effects of
generic drug usage in inpatient clinics in Turkey, icompared to
brand names. METHODS: Data was collected from one univer-
sity hospital, internal medicine inpatient service for 1 month. A
total of 62 patients were treated with an antibiotic. The antibi-
otic’s name, dosage and the duration of use were recorded by
the nurses. The price of the antibiotics were extracted from the
Ministry of Health’s ofﬁcial price list. We compared the cost of
the bio-equivalent and the cheapest generic drugs with the origi-
nal drugs. RESULTS: During the month, the cost of the antibi-
otics used at the internal medicine inpatient clinic was €1136,
compared to the cheapst generics, which was €1013. In this
clinic, €2,2 per patient more was paid for the brand name anti-
biotics each month. If the 1400–1600 patients being treated with
antibiotic in this hospital per year are considered, an average of
€3300/month or €39,600/year is being paid for brand name
antibiotics. CONCLUSION: Considering antibiotics are the
most common used medication in Turkey (17% of total drug
usage), it can easily be understood how the use of Brand Name
drugs rather than Generics would lead to a vast economic
burden. This shows the importance of promoting the use of
generic antibiotics and the need for cost-minimalization analysis.
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OBJECTIVES: To estimate the cost and mortality impact of
stockpiling pre-pandemic inﬂuenza vaccine for Germany, from
a societal perspective. METHODS: A static decision analytic
model was developed to examine the balance between stockpil-
ing costs and potential cost-savings on primary care, medication,
hospitalization and productivity losses and to assess the number
of prevented deaths. The applied time horizon was ﬁve years. In
the base-case, the annual probability of a pandemic, the clinical
attack rate and case fatality rate in patients not receiving any
anti-viral medication were conservatively estimated at 3%, 30%
and 1%, respectively. The vaccine efﬁcacy was assumed to be
65%. The effect of anti-viral medication on costs and mortality
was considered. Stockpiling costs included acquisition, storage,
expected replacement and expected administration costs of the
vaccine. Productivity costs were estimated using the human
capital approach. All costs were expressed in €2008. Costs but
not deaths were discounted at 5% per year. Extensive univariate
and probabilistic sensitivity analyses were performed. RESULTS:
Stockpiling of pre-pandemic inﬂuenza vaccine was predicted to
cost €1.54 billion and avoid €7.48 billion direct and productivity
costs thus rendering net savings of €5.94 billion, (95% CI: €53
million; €16.3 billion). In addition, 17,711 deaths could be
avoided. The probability of stockpiling vaccine being cost-saving
was estimated at 97.7%. The most inﬂuential model parameters
were the annual risk of a pandemic, followed by the case fatality
rate. These results are likely to be conservative as herd immunity
and macroeconomic effects were not included. CONCLUSIONS:
Stockpiling of pre-pandemic vaccine can be considered a domi-
nant strategy for Germany as it is predicted to lead to cost-
savings and to avoid a considerable number of deaths.
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OBJECTIVES: To review the socio-economic impact of avian
inﬂuenza in South-East Asian nations and neighbouring high risk
countries. METHODS: The information was retrieved from
the websites of World Bank, United Nations, clinicaltrials.gov,
Medline and relevant grey literature from 1995 to 2008. Only
English language articles and those covering South East Asia and
neighbouring nations were analysed. Number of cases of avian
inﬂuenza diagnosed, deaths in humans and poultry and associ-
ated socioeconomic impact were the outcomes of interest.
RESULTS: Of the 1973 citations, 134 met the inclusion criteria.
As per World Organisation for Animal Health, 6435 outbreaks
of avian inﬂuenza in poultry (4470 from South East Asia) have
been reported in 48 countries till June 2008. Fourteen countries
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have conﬁrmed 383 human cases with a fatality rate of 63%
(241/383) as per WHO May 2008 data. The major share is from
three South East Asian (SEA) countries—Vietnam, Thailand and
Indonesia, which together accounted to 177 deaths from 264
cases. Poultry sector contributes 1.2–2.4% of GDP in East Asian
and paciﬁc countries. Bird ﬂu has encroached poultry trade in
South East Asia killing more than 120 million birds with a gross
economic loss of US$10 billion compared to 300 million birds
killed globally with economic loss of US$20 billion (0.5–1% fall
in GDP) since 2003. The impact extends not only to poultry
farmers but also to upstream and downstream sectors (poultry
trade, breeding farms, tourism etc.). A recent analysis has pro-
jected that a future pandemic could kill 5–150 million people
leading to a 3.1–5.1% loss of world GDP (US$1.2–2 trillion).
CONCLUSIONS: Health and economic losses have posed a
major challenge to South East Asia. Appropriate and timely
measures are required to prevent a future pandemic which could
be devastating to Asia and rest of the world.
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OBJECTIVES: Human Papilloma Virus (HPV) is responsible for
both benign and malignant genital disease. The objective of this
study was to review the available epidemiological and cost in-
formation for genital warts (GW), with a focus on the female
population, the current target for HPV vaccination in Italy.
METHODS: The study analyzed scientiﬁc literature, data from
the Italian Centres of Surveillance of Sexually Transmitted Infec-
tions (MST), the National Hospital Discharge and the National
Drug Utilisation databases. National tariffs for ambulatory visits,
hospitalizations and drugs costs were used to estimate the overall
cost of GW disease for the Italian National Health System
(NHS). The overall cost for prevention and treatment of cervical
cancer was taken from La Torre 2007. RESULTS: No Italian
speciﬁc publications were found regarding GW epidemiology;
however from applying European incidence rates to the female
Italian population, 30,000 new GW cases/year were estimated.
According to MST data, there were 8,000 public clinic visits
relating to female GWs (20,000 visits for male GWs), suggestive
of a considerable use of private gynaecologists. In 2004 hospi-
talizations due to female GWs totalled 512 plus 1728 day-
admissions. Including the cost of the speciﬁc medicines (approx.
€2.4 M/year for imiquimod), the overall cost to the Italian NHS
was estimated as €4.3 M per year for the diagnosis and treatment
of female GWs (approx. 9.2M € for the whole population). Using
data from Merito (ISPOR Dublin 2007) estimating the average
cost for outpatient management of GWs as €147/case, the total
expenditure for the management of the GWs in the Italian female
population could be up to €7.1 M. CONCLUSIONS: The NHS
expenditure for the management of GW in the Italian female
population was estimated to represent 2.1–4.4% of the total
expenditure for prevention and treatment of HPV-related cervical
cancer disease.
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OBJECTIVES: Chronic Hepatitis C virus (HCV) and Hepatitis
B virus (HBV) are the two leading causes of liver disease in the
world. Approximately 2%-10% of HCV patients worldwide are
estimated to also have HBV, resulting in greater disease burden.
We analyze insurance claims to assess resource use and costs
among managed care enrollees with chronic HCV and HBV
co-infection compared to those with chronic HCV alone.
METHODS:AUS claims database spanning the period January 1,
2002 toDecember 31, 2006was retrospectively analyzed. Patients
were classiﬁed into 2 groups: 1) chronic HCV without HBV or
HIV (N = 27,296), and 2) chronic HCV and HBV co-infection
without HIV (N = 2,525). An index date was set as the date of
the ﬁrst observed chronic HCV diagnosis or date of diagnosis of
co-infection. Patients had continuous plan enrollment for 3
months pre- and 12 months post-index. Mean per patient use
and costs of all medical and pharmacy services were assessed over
12 months post-index. RESULTS: Patients with HCV alone had
61 encounters and total cost of $20,258 compared to 67 encoun-
ters and total cost of $23,494 for co-infected patients (P < 0.05).
Hospitalization rates were similar across the groups but, per
patient hospital costs were more than $2000 greater for
co-infected patients (P < 0.05). Co-infected patients stayed longer
in the hospital (9.2 vs. 7.6 days, P < 0.05) and also had higher
costs for laboratory services and other outpatient/ ancillary ser-
vices (both P < 0.05). There were no signiﬁcant differences in
encounters and costs related to physician ofﬁce and emergency
department visits. After controlling for demographics and comor-
bidities inmultivariate analyses, co-infected patients had 4.4more
encounters and incurred $1885 more in total costs compared
to those with HCV alone (P < 0.05). CONCLUSIONS: Chronic
HCV and HBV co-infection leads to signiﬁcantly greater con-
sumption of health care resources and imposes greater burden on
managed compared to chronic HCV alone.
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OBJECTIVES: We generate national estimates of inpatient costs,
length of stay (LOS), and probability of death among patients
infected with Hepatitis C Virus (HCV), human immunodeﬁ-
ciency virus (HIV), and those co-infected with both. METHODS:
Discharge data from the 2005 HCUP Nationwide Inpatient
Sample, the largest all-payer inpatient care database in the United
States (US) were analyzed. Hospitalizations were categorized into
mutually exclusive groups based on ICD-9-CM diagnosis codes:
HCV only, HIV only, HCV and HIV, and no HCV or HIV.
Weighted estimates of LOS, costs, and probability of death were
calculated for each stay. RESULTS: There were 390,975 hospi-
talizations for HCV, 136,596 for HIV, and 26,000 for HCV and
HIV co-infections. The average LOS for HCV-related hospital-
izations was 6.03 days. LOS for HIV-related hospitalizations was
higher at 7.87 days (P < 0.0001), similar to the LOS for hospi-
talizations pertaining to HCV and HIV co-infection (7.88 days).
In comparison, hospitalizations not related to HCV or HIV had
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